Developed initially to manage type 2 diabetes, these drugs work by mimicking the action of the natural hormone GLP-1
Both the Wegovy [1] and Zepbound [2] labels recommend against use while breastfeeding, weighing the developmental risk to the infant against the benefit to the mother
In mouse models of inflammatory bowel disease, orally or systemically administered KPV reduced weight loss, lowered colonic myeloperoxidase activity, and improved histological markers of colitis

TUE guidance documents including new regulations on glucocorticoids In order to assist physicians and athletes, WADA will update and publish shortly, on its website, the following guidance documents on managing TUEs to include the new regulations on glucocorticoids: General document on glucocorticoids and TUEs (to be available mid-October 2021) Checklists on a number of medical conditions for which glucocorticoids may be used (to be available early November 2021) TUE Physician Guidelines for TUE Committees on how to evaluate TUE requests for glucocorticoids for different medical conditions (to be available early November 2021) Educational resources In addition to the guidance documents listed above, WADA has provided, or will provide, a number of educational resources as part of its Code Implementation Support Program (CISP), which can be accessed on the Agencys Anti-Doping Education and Learning Platform (ADEL)

Its depletion has been observed in cases of fatty liver disease, while restoration of NAD + levels has been shown to mitigate the initiation and progression of disease